Scalper1 News
Nivalis Therapeutics (NVLS) stock rose on its first day of trading Wednesday in an IPO that raised $77 million for the biotech company. Nivalis is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule therapeutics for patients with cystic fibrosis. Nivalis priced 5.5 million shares at 14, the midpoint of its estimated price range. The company initially planned to sell 4.3 million shares. Nivalis Scalper1 News
Scalper1 News